Supply of Pharmaceutical Products

⁠⁠⁠The scope of products to be covered under the tender will include the following:
* Sole supply or drugs that are patent protected; and
* Generic Pharmaceutical Products with multiple providers for the same product.

Products will be categorised into two broad market segments:
Drug Group A – Sole Supply Drugs: These are pharmaceutical products which have a single supplier in the market. Patented and/or highly specialised drugs are to be tendered under this Drug Group.
Drug Group B – Competitive Drugs: These are pharmaceutical products where there is effective competition in the market. Generic drugs are to be tendered under this Drug Group.

Contract Design

The proposed new arrangement will be a significant redesign of the current Pharmaceutical Products Contract - HCNS110709 and it is anticipated that it will include (but not be limited to) the following features:
* Improving the supply of products to WA Health: A significantly expanded range of pharmaceutical products to promote aggregation of spend across WA Health and using more effective measures to ensure the reliability to supply.
* Improving WA Health’s response to market changes: Provision to re-test the market using supplementary (refresh) tendering processes on an ad hoc, as required basis.
* Greater flexibility in the State-wide arrangement: Provision to allow WA Public Health Care Units to approach Suppliers to negotiate the supply of patented pharmaceutical products at a site level.